Reference
Each table below is read out of the same dated ledger the molecule index renders. No cell on any of them is typed by hand, which is what lets a table stay correct when a status flips: one edit to the registry re-renders every row on every page at once.
Each table states its denominator above the data. A count on these pages is a count of the substances this index tracks, stated as such; where a total exists only in a source this index has not verified, the table declines to print one rather than estimating it.
How did the advisory committee vote on each peptide, and what does a vote do?
The committee recommended six peptides for the section 503A list and rejected one; the votes are advisory, FDA rulemaking must finish before any of the six may be compounded, and as of the dates below none may.
What happened to United States peptide compounding law in 2026, in order?
Twelve peptides left a prohibition category in April and an advisory committee recommended six of them for listing in July; no peptide reviewed in 2026 became lawful to compound, because the FDA has issued no final rule.
What became of each peptide's nomination to the 503A bulks list?
Seven dispositions account for every molecule in this index, and the two most often reported as approvals — removal from Category 2 without listing, and withdrawal by the nominators — are the opposite of one.
The peptides removed from Category 2 in April 2026 — are they lawful now?
No. Removal ended an explicit prohibition and conferred no authorization; the substances were not added to Category 1, they sit on no list, and no lawful compounding route followed from the removal.
Which peptides in this index are actually approved drugs?
Ten, and their approvals are narrow: an approval belongs to a product in a stated indication, not to a molecule in every use a seller can imagine for it.
How many human clinical trials exist for each peptide in this index?
Far fewer than the counts suggest: four molecules return no trial-type record at all, and on several of the rest the records that are returned measure the body's own peptide rather than the compound anyone is selling.
Which peptides in this index are prohibited in sport, and under which class?
Twelve of the 40 molecules this index tracks are named on the 2026 Prohibited List, and the other 28 are not named — which is not the same as permitted, because every relevant section is expressly non-exhaustive and S0 prohibits any substance with no current regulatory approval for human therapeutic use.
Has the FDA finalized anything on the peptides recommended in July 2026?
No. As of September 2026, not one of the six peptides the advisory committee recommended has an FDA final action on record, and the most recent section 503A bulks-list rule was published on February 19, 2019 — before every event this index tracks.
They do not adjudicate a named seller, and they do not anticipate rulemaking: a recommended molecule is recorded as recommended and pending, whatever the market expects. The method states both rules, the evidence reviews argue from the same record, and the glossary defines the terms every table uses.